Investment analysts at Rodman & Renshaw began coverage on shares of CytoDyn Inc (OTC:CYDY) in a research report issued to clients and investors on Thursday. The firm set a “buy” rating and a $1.60 price target on the stock. Rodman & Renshaw’s price target indicates a potential upside of 131.88% from the company’s previous close.

Shares of CytoDyn (OTC:CYDY) traded up 7.46% during trading on Thursday, hitting $0.72. 1,539,804 shares of the company traded hands. The stock’s market cap is $89.66 million. The firm has a 50 day moving average price of $0.89 and a 200-day moving average price of $1.04. CytoDyn has a one year low of $0.63 and a one year high of $1.57.

CytoDyn Company Profile

CytoDyn Inc is a clinical-stage biotechnology company. The Company is focused on the clinical development and commercialization of humanized monoclonal antibodies to treat Human Immunodeficiency Virus (HIV) infection. The Company’s lead product candidate, PRO 140, belongs to a class of HIV therapies known as entry inhibitors that block HIV from entering into and infecting certain cells.

Receive News & Stock Ratings for CytoDyn Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytoDyn Inc and related stocks with our FREE daily email newsletter.